ESR1 and breast carcinoma: Therefore, we targeted downstream ER signaling events by using a United States Food and Drug Administration approved cyclin-dependent kinase (CDK) 4/6 inhibitor for metastatic ER+ breast cancer, palbociclib, based on our previous observation that palbociclib antagonized tumor growth driven by ESR1 point activating mutations.